-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, F7dmde+SHqdVTx3BdpiNG1moSvBgFHYs7/0VyEqLmmBMnfkG4Wc99BETdmZscsDr eQJnVGPNu5853IpsJo9z8w== 0000950137-06-000064.txt : 20060105 0000950137-06-000064.hdr.sgml : 20060105 20060104215032 ACCESSION NUMBER: 0000950137-06-000064 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20060101 ITEM INFORMATION: Entry into a Material Definitive Agreement FILED AS OF DATE: 20060105 DATE AS OF CHANGE: 20060104 FILER: COMPANY DATA: COMPANY CONFORMED NAME: SPECTRUM PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000831547 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 930979187 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-28782 FILM NUMBER: 06510389 BUSINESS ADDRESS: STREET 1: 157 TECHNOLOGY DR CITY: IRVINE STATE: CA ZIP: 92618 BUSINESS PHONE: 9497886700 MAIL ADDRESS: STREET 1: 157 TECHNOLOGY DR CITY: IRVINE STATE: CA ZIP: 92618 FORMER COMPANY: FORMER CONFORMED NAME: NEOTHERAPEUTICS INC DATE OF NAME CHANGE: 19960819 FORMER COMPANY: FORMER CONFORMED NAME: AMERICUS FUNDING CORP DATE OF NAME CHANGE: 19920703 8-K 1 a15930e8vk.htm FORM 8-K e8vk
Table of Contents

 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES AND EXCHANGE ACT OF 1934
January 5, 2006 (January 1, 2006)
Date of Report (Date of earliest event reported)
 
SPECTRUM PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
         
Delaware
(State or other Jurisdiction
of Incorporation) 		  000-28782
(Commission File Number) 		  93-0979187
(IRS Employer
Identification Number)
         
157 Technology Drive
Irvine, California
(Address of principal executive offices) 		      92618
(Zip Code)
(949) 788-6700
(Registrant’s telephone number, including area code)
N/A
(Former Name or Former Address, if Changed Since Last Report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 

 

TABLE OF CONTENTS

Item 1.01 Entry Into Material Definitive Agreement
SIGNATURES

Table of Contents

Item 1.01 Entry Into Material Definitive Agreement
     The Compensation Committee of the Board of Directors (“Compensation Committee”) of Spectrum Pharmaceuticals, Inc. (the “Company”) approved a restricted stock grant effective as of January 1, 2006 under the Company’s 2003 Amended and Restated Incentive Award Plan (the “Plan”) of 80,000 shares of restricted stock to Rajesh C. Shrotriya, Chairman, Chief Executive Officer and President of the Company. No purchase price was payable for the shares of restricted stock issued. The shares of restricted stock will vest in four annual installments of 25% each on January 1, 2006, January 1, 2007, January 1, 2008 and January 1, 2009, subject to the grant recipient’s continued employment or service with the Company through the specified vesting date. Vesting is accelerated upon the happening of certain events, including upon a change in control of the Company in certain circumstances. Unvested shares of restricted stock are subject to forfeiture immediately upon the recipient’s termination of employment or service with the Company, provided that the Compensation Committee has the discretion to waive such forfeiture restrictions at any time. Additional terms of the grant are set forth in a Restricted Stock Agreement between the Company and the recipient. The Compensation Committee has the discretion to make future awards under the Plan (including additional restricted stock grants) and has the discretion to determine the terms and conditions of such grants consistent with the Plan, including the identity of grantees, the type of each award granted, the size of each award, the purchase price to be paid (if any) for shares of common stock subject to each award, the vesting schedule (if any) applicable to each award and the forfeiture restrictions (if any) applicable to each award.

 

Table of Contents

SIGNATURES
     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
         
  SPECTRUM PHARMACEUTICALS, INC.
 		  
Date: January 5, 2006  By:   /s/ Shyam Kumaria    
    Name:   Shyam Kumaria   
    Title:   V.P. Finance   
 

 

-----END PRIVACY-ENHANCED MESSAGE-----